Congenital Hypothyroidism: Causes, Screening, Treatment, and Long-Term Outcomes

Congenital hypothyroidism (CH) is thyroid hormone deficiency present at or before birth, most often caused by a thyroid gland that failed to form, migrated to an abnormal position, or produces hormone inefficiently. It is distinct from Hashimoto's thyroiditis and other forms of acquired hypothyroidism, which develop later in life through an autoimmune process, and it is the opposite condition of Graves' disease, which causes excess rather than deficient thyroid hormone. The reader-relevant question is not simply "what is CH" but what a screen-positive newborn result actually requires next, and how quickly, because the timing of treatment is what the outcome evidence turns on.

Congenital hypothyroidism occurs in roughly 1 in 2,000 to 1 in 4,000 live births in iodine-sufficient populations, most commonly because the thyroid gland is absent, ectopic, or underdeveloped (thyroid dysgenesis). Universal newborn heel-prick screening for TSH or T4, standard across the United States and most high-income countries since the late twentieth century, allows diagnosis before symptoms appear. Pediatric endocrinology guidelines generally support starting levothyroxine promptly once the diagnosis is confirmed by serum testing, because older cohort studies link delayed correction of thyroid hormone in infancy to lower measured IQ, though the exact dose-response relationship varies across studies and should be confirmed against the primary literature rather than treated as a fixed number.

What is happening inside the thyroid

The thyroid gland sits at the front of the neck and produces thyroxine (T4) and triiodothyronine (T3), the hormones that drive brain myelination, synapse formation, and neuronal migration during fetal life and the first few years after birth. The hypothalamic-pituitary-thyroid axis regulates hormone output: when circulating T4 is low, the pituitary raises TSH in an attempt to stimulate more hormone production. This TSH rise is the signal that newborn screening programs are built to detect.

CH is generally grouped into two categories. Permanent CH, caused by structural gland abnormalities (dysgenesis) or inherited defects in hormone synthesis (dyshormonogenesis), requires lifelong levothyroxine replacement. Transient CH can result from maternal antithyroid antibodies crossing the placenta, iodine deficiency or iodine excess around the time of birth, or prematurity, and it typically resolves over weeks to months. Distinguishing the two at diagnosis is not always possible; it is usually clarified later with a supervised medication trial once the child is a toddler.

How common is it, and who is at higher risk

The commonly cited incidence range for CH is 1 in 2,000 to 1 in 4,000 live births in countries with adequate iodine intake. Reported incidence has risen in some regions over recent decades, which is generally attributed to lower TSH cutoffs in screening programs that now catch milder cases previously missed, rather than a true rise in disease frequency. Girls are affected more often than boys for the structural (dysgenesis) causes. Children with Down syndrome have a clearly elevated risk of CH compared with the general population; the exact fold-increase reported varies between studies and should be checked against a current primary source before being cited as a precise figure. Very preterm infants can show a different pattern of low thyroid hormone without a corresponding TSH rise, which is why some neonatal units use separate screening protocols for this group.

Causes

Thyroid dysgenesis (an absent, ectopic, or underdeveloped gland) is the leading cause of permanent CH. An ectopic gland that never fully descended from the back of the tongue to its normal position in the neck is the most frequent subtype; complete absence of detectable thyroid tissue and a small but correctly positioned gland account for most of the remainder. A minority of cases are linked to mutations in transcription factor genes such as NKX2-1, FOXE1, or PAX8, but most dysgenesis occurs without an identified genetic cause.

Dyshormonogenesis, an inherited (usually autosomal recessive) defect in the machinery that makes thyroid hormone, accounts for a substantial minority of permanent CH cases. Because the gland itself is structurally present, it often enlarges into a goiter as TSH rises in an attempt to compensate.

Transient causes include maternal Graves' disease treated with antithyroid drugs during pregnancy, maternal TSH-receptor-blocking antibodies (seen with some autoimmune thyroid disease) that cross the placenta and temporarily occupy the infant's TSH receptors, iodine deficiency, and iodine excess from antiseptic skin preparations used around preterm deliveries. Iodine deficiency remains a major global cause of preventable thyroid dysfunction and intellectual disability; the World Health Organization has published detailed estimates and monitoring guidance on this (WHO, Assessment of Iodine Deficiency Disorders and Monitoring Their Elimination).

How newborn screening works, and what a positive result means

A heel-prick blood sample is collected on filter paper, typically between 24 and 72 hours of life, timed to avoid the normal TSH surge that occurs in the first hours after delivery. Infants discharged before 24 hours are usually recommended for a repeat sample at around 10 to 14 days to reduce false negatives.

Most North American and European programs use a TSH-primary strategy: an elevated TSH on the screening card triggers urgent confirmatory serum testing. This approach reliably detects primary CH (the thyroid gland itself is the problem) but can miss central hypothyroidism, a much rarer situation where the pituitary or hypothalamus fails to signal the thyroid properly and TSH may be normal or low despite low T4. Some programs, including a subset of U.S. states, use a T4-primary strategy that reflexes to TSH testing, which can catch both types but is more resource-intensive.

Any screen-positive result requires prompt confirmatory serum TSH and free T4. A clearly elevated TSH together with a low free T4 confirms the diagnosis and should prompt same-day clinical evaluation. Thyroid ultrasound or radionuclide imaging can help characterize the gland's anatomy, but imaging should never delay starting treatment once the diagnosis is confirmed.

Treatment

Oral levothyroxine is the standard treatment for confirmed CH. Pediatric endocrinology guidance generally supports starting treatment as soon as the diagnosis is confirmed, with the goal of normalizing free T4 within about two weeks and TSH within about a month. The specific starting dose, and any adjustment, is a clinical decision made by the treating pediatrician or pediatric endocrinologist based on the infant's weight, initial hormone levels, and clinical picture; this article does not provide an individualized dosing recommendation, and a commonly cited starting range in the literature (roughly 10 to 15 mcg per kg per day for term infants) should be confirmed against current guideline documents rather than used to self-adjust a dose.

Levothyroxine tablets are typically crushed and given in a small amount of breast milk or water rather than mixed into a full bottle feed, so that a partially finished feed does not result in a partial dose. Soy-based formula, calcium-fortified products, and iron supplements can reduce levothyroxine absorption and are generally separated from dosing by a couple of hours, though families should follow their own clinician's specific instructions rather than a generic separation window.

After starting treatment, TSH and free T4 are checked repeatedly through infancy and early childhood, tapering in frequency as levels stabilize. Over-treatment, meaning TSH persistently suppressed well below the normal range, is a recognized concern in infancy because of possible effects on bone maturation and skull suture closure; this is a reason regular monitoring continues even after the child appears well.

At around two to three years of age, children whose thyroid function has looked stable on a low or decreasing dose may be offered a supervised trial off medication to determine whether the original CH was permanent or transient. TSH is rechecked several weeks after stopping; a clearly elevated result supports permanent CH, and a normal result supports a transient diagnosis, usually followed by ongoing annual monitoring.

Neurodevelopmental outcomes with early treatment

When CH is caught on newborn screening and treatment starts within the first weeks of life, the general finding across long-running cohort studies is that most children reach normal-range IQ scores. Some cohort work also suggests that children with the most severe hormone deficiency at diagnosis (very low initial T4, complete absence of thyroid tissue) may still show small differences on specific tests of executive function or visuomotor skills compared with unaffected peers, even when full-scale IQ is normal. The precise numeric size of these differences varies by study population and test battery, and readers should treat any single percentage or point estimate from this literature as needing verification against the specific paper rather than as a fixed universal figure.

What is established: early, guideline-consistent treatment produces good average outcomes and prevents the severe intellectual disability that was historically associated with untreated CH. What is plausible but not settled: the exact quantitative relationship between how many days or weeks treatment is delayed and how much measurable cognitive risk results. What is not established from the material available for this page: individualized prediction of a specific child's outcome based on a single lab value at diagnosis.

Decision framework: from a screening result to a treatment decision

This is a general orientation framework for parents and non-specialist clinicians reading a newborn screening result. It does not replace direct guidance from the treating pediatrician or pediatric endocrinologist, and it does not set an individual dose.

Seek urgent medical attention rather than waiting for a routine appointment if an infant with suspected or confirmed CH develops significant lethargy, very poor feeding, a large umbilical hernia, prolonged constipation, or jaundice that persists beyond the first couple of weeks of life. These can be signs of untreated or under-treated hypothyroidism and warrant same-day evaluation.

Related thyroid conditions, and why they are sometimes confused with CH

Hashimoto's thyroiditis is an autoimmune condition that develops later in childhood or adulthood, unrelated in mechanism to CH, in which the immune system generates antibodies against thyroid tissue and gradually reduces hormone output. It is generally described as the most common cause of acquired (as opposed to congenital) hypothyroidism in iodine-sufficient countries.

Subclinical hypothyroidism describes a mildly elevated TSH with a normal free T4. In infants, TSH physiologically starts very high right after birth and falls over the first week, so interpreting a borderline TSH in a very young infant requires an age-appropriate reference range rather than the adult cutoff. In adults, professional society guidance generally supports treatment when TSH is clearly above about 10 mIU/L, with treatment for milder elevations considered case by case depending on symptoms and antibody status; readers should confirm the exact current thresholds directly from an accountable guideline body such as the American Thyroid Association rather than from a paraphrase, since these numeric thresholds are the kind of detail that gets revised between guideline versions.

Graves' disease causes hyperthyroidism, the opposite hormonal direction from CH, through antibodies that continuously stimulate the thyroid. Neonatal Graves' disease is a separate, temporary condition seen in infants of mothers with active Graves' disease, caused by maternal antibodies crossing the placenta; it resolves as those maternal antibodies clear over the following weeks, and its treatment is directed by a pediatric specialist rather than a general dosing formula.

Iodine and thyroid health across life stages

Adequate iodine intake supports thyroid hormone production throughout life, with higher requirements during pregnancy and breastfeeding than at other times. The World Health Organization's iodine deficiency monitoring guidance describes deficiency as a major, preventable global cause of thyroid dysfunction and, in its most severe untreated form, intellectual disability (WHO, 2007). For a family with an infant on levothyroxine for CH, iodine adequacy in the maternal or infant diet remains relevant if the child's own thyroid tissue, even if underdeveloped, still contributes any baseline hormone production.

Genetics and family counseling

Most CH is sporadic rather than clearly inherited. Genetic evaluation is not part of routine newborn care but is reasonable to discuss with a pediatric endocrinologist when there is a family history of thyroid dysgenesis or dyshormonogenesis, when more than one sibling is affected, or when features suggesting a genetic syndrome are present (for example, the combination of CH with neonatal breathing difficulty and later movement problems, which has been described with NKX2-1 mutations). Recurrence risk in a future pregnancy differs substantially depending on whether the underlying cause is an isolated structural defect (generally lower recurrence risk) or an inherited enzyme defect (which follows autosomal recessive inheritance and carries a materially higher recurrence risk); a genetics or pediatric endocrinology consultation is the appropriate route to an individualized estimate.

What is established, what is uncertain, and what this page cannot tell you

Established: universal newborn screening for CH, followed by prompt levothyroxine treatment, prevents the severe intellectual disability that was common before screening existed, and most treated children reach normal-range cognitive outcomes.

Plausible but not fully settled from the material reviewed here: the exact quantitative cost, in IQ points or specific cognitive domains, of each additional week of treatment delay, and the exact fold-increase in CH risk associated with Down syndrome. Both figures appear in various forms across the literature, and a precise number should be sourced from the specific primary study before being repeated as fact.

Not established, and outside the scope of general education: what a specific child's dose should be, what a specific infant's screening result means in isolation, and whether a specific case is transient or permanent before the toddler-age medication trial. These require direct evaluation by the treating clinician.

References

• World Health Organization. Assessment of Iodine Deficiency Disorders and Monitoring Their Elimination, 3rd edition. Geneva: WHO, 2007. https://www.who.int/publications/i/item/9789241595827

This article previously carried a longer numbered reference list, including a direct quotation attributed to a professional society guideline. The specific journal citations and the quotation could not be verified against the primary sources available for this revision and have been removed or rewritten as general, unattributed statements rather than left as unverified numbered citations. A qualified reviewer should attach verified primary sources (guideline documents from the American Academy of Pediatrics, European Society for Paediatric Endocrinology, and American Thyroid Association, and the specific cohort studies referenced in the outcomes section) before publication.